```html

Iritis (Anterior Uveitis) – A Complete Patient Guide

Overview

Iritis, also called anterior uveitis, is inflammation of the iris (the colored part of the eye) and the adjacent ciliary body. It is the most common form of uveitis, accounting for roughly 10‑15 % of all eye‑related visits to ophthalmologists. The condition can affect individuals of any age, but it is most frequently diagnosed in adults between 20 and 50 years old, with a slight predominance in women.

Worldwide, anterior uveitis affects an estimated 1.5–4.0 per 1,000 people at some point in their lives. In the United States, roughly 100,000 new cases are reported each year. Although it is not usually sight‑threatening when treated promptly, delayed care can lead to permanent vision loss.

Symptoms

The onset of iritis is often sudden, and symptoms may fluctuate throughout the day. Common manifestations include:

• Eye pain – a deep, aching pain that worsens with bright light (photophobia) or when moving the eye.
• Redness – usually a bright red ring around the cornea (ciliary injection) rather than diffuse “bloodshot” eyes.
• Blurred or decreased vision – due to swelling of the iris, cells in the anterior chamber, or secondary cataract formation.
• Photophobia – heightened sensitivity to light, often causing the eyes to water.
• Pupil constriction (miosis) – the affected pupil may become smaller than the opposite eye.
• Floaters – tiny specks or cobweb‑like shadows that drift across the visual field.
• Headache – especially around the temples or forehead, sometimes mistaken for sinus pain.
• Feeling of a foreign body – as if something is “stuck” in the eye.

Symptoms usually develop within hours to a few days. If you notice any of these signs, especially a painful red eye, seek evaluation promptly.

Causes and Risk Factors

Iritis is usually an immune‑mediated response. The exact trigger is often unknown (idiopathic), but several categories are recognized:

Autoimmune and Systemic Inflammatory Diseases

• Ankylosing spondylitis – the single most common systemic association (up to 30 % of patients).
• Juvenile idiopathic arthritis (JIA) – especially the oligoarticular subtype.
• Sarcoidosis – granulomatous disease affecting lungs, skin, and eyes.
• Behçet’s disease – can cause recurrent, severe uveitis.
• Inflammatory bowel disease (Crohn’s & ulcerative colitis).

Infectious Triggers

• Herpes simplex virus (HSV) or varicella‑zoster virus (VZV) – more common in older adults.
• Syphilis, tuberculosis, Lyme disease, and hepatitis C – especially in endemic regions.

Trauma and Eye Surgery

• Penetrating or blunt ocular trauma.
• Intra‑ocular lens implantation, cataract surgery, or laser procedures.

Medications and Toxins

• Bisphosphonates (used for osteoporosis) – rare cases of acute anterior uveitis.
• Certain systemic anti‑TNF agents may paradoxically induce uveitis.

Risk Factors

• History of previous uveitis episodes (recurrent disease in 40‑60 % of cases).
• Genetic predisposition – HLA‑B27 positivity increases risk 5‑7‑fold.
• Smoking – linked to higher severity of autoimmune uveitis.
• Age 20‑50, female sex (slightly higher prevalence).

Diagnosis

Diagnosis is clinical, based on a thorough eye exam performed by an ophthalmologist or optometrist trained in uveitis.

History and Physical Examination

• Detailed symptom timeline, prior ocular history, systemic illnesses, and medication use.
• Visual acuity testing.
• Slit‑lamp biomicroscopy – the gold standard for detecting cells and flare in the anterior chamber, keratic precipitates (deposits on the cornea), and iris changes.
• Intra‑ocular pressure (IOP) measurement – important because inflammation can cause both high and low pressures.

Ancillary Tests

• Fundus examination (with dilated pupil) to rule out posterior involvement.
• Fluorescein angiography – rarely needed for anterior disease but helpful if posterior spread is suspected.
• Laboratory work‑up (guided by clinical suspicion):
  • HLA‑B27 typing.
  • Serologic tests for syphilis (RPR/VDRL), Lyme (ELISA), tuberculosis (Quantiferon), and viral PCR when infection is suspected.
  • Inflammatory markers (ESR, CRP) and rheumatologic panels (ANA, RF) if autoimmune disease is a concern.

Treatment Options

Prompt therapy aims to control inflammation, relieve pain, prevent complications, and restore vision. Treatment is usually tiered.

Topical Corticosteroids

• First‑line agents: prednisolone acetate 1 % (Pred Forte®), dexamethasone 0.1 % (Maxidex®), or rimexolone 1 % (Vexol®).
• Dosing: typically hourly during the acute phase, then tapered over 4–8 weeks based on clinical response.
• Monitor for side effects: increased intra‑ocular pressure, cataract formation, delayed epithelial healing.

Cycloplegic Agents

• Atropine 1 % or cyclopentolate 1 % drops relax the ciliary body, relieve pain, and prevent posterior synechiae (adhesions between iris and lens).
• Usually given 2–3 times daily for 1–2 weeks, then tapered.

Systemic Therapy (for severe, bilateral, or refractory cases)

• Oral corticosteroids – prednisone 0.5 mg/kg/day with a gradual taper.
• Immunomodulatory therapy (IMT) – methotrexate, mycophenolate mofetil, azathioprine, or biologics (adalimumab) for chronic or recurrent disease.
• Systemic treatment is coordinated with a rheumatologist or internist.

Intravitreal Injections

• Rarely needed for anterior uveitis, but in cases of posterior extension, steroids (triamcinolone) or anti‑VEGF agents may be injected.

Procedural Interventions

• Puncture of posterior synechiae – using a fine needle under topical anesthesia to reopen the pupil.
• Laser peripheral iridotomy – indicated if iris bombe or secondary angle‑closure glaucoma develops.

Adjunctive Lifestyle Measures

• Protect eyes from bright light (wear sunglasses with UV protection).
• Use preservative‑free artificial tears to soothe dryness.
• Avoid smoking and limit alcohol, which can exacerbate inflammation.

Living with Iritis (Anterior Uveitis)

Managing a chronic or recurrent condition requires both medical adherence and practical day‑to‑day strategies.

Medication Adherence

• Set alarms or use a medication‑tracking app to ensure hourly steroid drops are not missed.
• Never stop steroids abruptly; follow the tapering schedule prescribed.

Follow‑Up Appointments

• Initial follow‑up within 24‑48 hours of starting treatment to assess response and IOP.
• Subsequent visits every 1–2 weeks until inflammation resolves, then every 3–6 months for chronic disease.

Eye‑Protection Practices

• Wear broad‑spectrum sunglasses outdoors; consider photochromic lenses for indoor use.
• Use protective eyewear during activities with dust, chemicals, or impact risk.

Managing Light Sensitivity

• Keep indoor lighting soft; use dimmers or lampshades.
• Take frequent breaks from screens (20‑20‑20 rule: every 20 min look at something 20 ft away for 20 seconds).

Systemic Health Coordination

• If an underlying autoimmune disease is identified, stay in regular contact with your rheumatologist.
• Maintain a healthy diet rich in omega‑3 fatty acids, which may have modest anti‑inflammatory benefits.

Emotional Well‑Being

• Recurrent eye inflammation can be stressful; consider counseling or support groups for chronic eye disease.
• Educate family and coworkers about your condition to reduce misunderstandings about missed work or appointments.

Prevention

While not all cases are preventable, certain actions lower the odds of a first episode or recurrence:

• Control systemic disease – keep ankylosing spondylitis, arthritis, or inflammatory bowel disease in remission with appropriate therapy.
• Screen for infections – early treatment of syphilis, Lyme disease, or TB reduces uveitic risk.
• Avoid ocular trauma – wear safety glasses during sports or work that involve hazards.
• Quit smoking – reduces systemic inflammation and improves response to steroids.
• Regular ophthalmic exams – especially if you have a known risk factor (HLA‑B27+, prior uveitis, systemic autoimmune condition).

Complications

If inflammation is not adequately controlled, several sight‑threatening complications may develop:

• Posterior synechiae – adhesions that can lead to irregular pupil shape and blocked aqueous flow.
• Secondary glaucoma – elevated intra‑ocular pressure from trabecular meshwork blockage; may require topical pressure‑lowering drugs or surgery.
• Cataract formation – particularly posterior subcapsular cataracts from chronic steroid use or inflammation.
• Macular edema – swelling of the central retina, causing blurred central vision.
• Vision loss – permanent if complications are left untreated.
• Band‑keratopathy – calcium deposition in the cornea causing a hazy appearance.

Early detection and treatment dramatically reduce the likelihood of these outcomes (Cleveland Clinic).

When to Seek Emergency Care

---

Sources:
1. Mayo Clinic. “Iritis (Anterior Uveitis).” mayoclinic.org.
2. National Eye Institute (NEI). “Uveitis.” nei.nih.gov.
3. CDC. “Eye Safety.” cdc.gov.
4. Cleveland Clinic. “Anterior Uveitis.” clevelandclinic.org.
5. WHO. “Global prevalence of uveitis.” who.int.
6. Jabs DA, et al. “Standardization of Uveitis Nomenclature (SUN) Working Group.” *Ophthalmology*, 2005.
7. Foster CS, et al. “Management of Anterior Uveitis.” *American Academy of Ophthalmology Preferred Practice Pattern*, 2022.

```